Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2008-07-01
2008-07-01
Kwon, Brian-Yong S (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S397000, C514S394000, C514S396000, C514S299000
Reexamination Certificate
active
07393857
ABSTRACT:
The present invention relates to a new use for compounds having 5-HT3(serotonin M) receptor antagonist activity, especially tropisetron, for the manufacture of a pharmaceutical composition for the treatment of a non-inflammatory local disease of the musculo-sceletal system, of a local irritation condition of a joint or tendon sheath, or for the local treatment a local manifestation at the locomotor apparatus of an inflammatory disease except for a crystal induced arthritis and a living pathogen induced inflammatory disease condition as long as the living pathogen is still present.
REFERENCES:
patent: 4877798 (1989-10-01), Sorensen
patent: 5063230 (1991-11-01), Pelletier et al.
patent: 5063231 (1991-11-01), Sanger et al.
patent: 5122528 (1992-06-01), Imondi
patent: 5202333 (1993-04-01), Berger et al.
patent: 5225407 (1993-07-01), Oakley et al.
patent: 5378686 (1995-01-01), Bennett
patent: 5442078 (1995-08-01), Cohen et al.
patent: 5491148 (1996-02-01), Berger et al.
patent: 5576317 (1996-11-01), Gonsalves
patent: 5703240 (1997-12-01), Armour et al.
patent: 5707642 (1998-01-01), Yue
patent: 5710161 (1998-01-01), Ladduwahetty et al.
patent: 5800385 (1998-09-01), Demopulos et al.
patent: 5820583 (1998-10-01), Demopulos et al.
patent: 5860950 (1999-01-01), Demopulos et al.
patent: 6009875 (2000-01-01), Hubbard, Jr.
patent: 6048859 (2000-04-01), Dorn et al.
patent: 6211171 (2001-04-01), Sawynok et al.
patent: 6384042 (2002-05-01), Farber et al.
patent: 6462065 (2002-10-01), Muller et al.
patent: 6541523 (2003-04-01), Iglehart, III
patent: 6623742 (2003-09-01), Voet
patent: 6642240 (2003-11-01), Alvaro et al.
patent: 10221831 (2004-02-01), None
patent: 0 189 002 (1986-07-01), None
patent: 0 507 637 (1992-10-01), None
patent: WO 94/01095 (1994-01-01), None
patent: WO 95/01793 (1995-01-01), None
patent: WO 9527490 (1995-10-01), None
patent: WO 96/19233 (1996-06-01), None
patent: WO 9853815 (1998-12-01), None
patent: WO 00/48597 (2000-08-01), None
“Fibromyalgia”, The Merck Manual Online Medical Library, www.meck.com, 2003.
“Fibromyalgia”, Goldenberg, D.L, www.patients.uptodate.com, 2007.
“Localized fibromyalgia in a child”, Bassan et al., Pediatric Anesthesia, abstract, vol. 5(4), pp. 263-265.
Chemical Abstracts AN 125:317390 “Serotoninergic Antagonists as Topical Antipruritic Agents”, (Japan 0082176, Aug. 27, 1996).
Chemical Abstracts XP-002149134 Giordano et al., “Topical Ondansetron Attenuates Nociceptive and Inflammatory Effects of Intradermal Capsaicin in Humans”, Europ. J. of Pharmacol., vol. 354, No. 1, pp. R13-R14 (1998).
Chemical Abstracts XP-002149139 Schwörer et al., “Treatment of Acute Gouty Arthritis With the 5-Hydroxytryptamine Antagonist Ondansetron”, Clin. Investig., vol. 72, No. 10, pp. 811-813 (1994).
Mansford, “Zeichen Für Einen Groβen Aufbruch”, Fortschritte der Med., vol. 108, Suppl. 82, pp. 4-9 (1990).
Society for Neuroscience, vol. 23, pp. 1540-1541 (1997)—[Abstracts 601.15-602.8].
Barnes et al., “Modulation of Neurogenic Inflammation: Novel Approaches to Inflammatory Disease”, Trends in Pharmacol. Sci. (TiPS), vol. 11, pp. 185-189 (1990).
Giordano et al., “Peripherally Administered Serotonin 5-HT3Receptor Antagonists Reduce Inflammatory Pain in Rats”, Europ. J. of Pharmacol., vol. 170, Nos. 1-2, pp. 83-86 (1989).
Glaum et al., “Identification of 5-HT3Binding Sites in Rat Spinal Cord Synaptosomal Membranes”, Europ. J. of Pharmacol., vol. 156, pp. 287-290 (1988).
Glaum et al., “Reversal of the Antinociceptive Effects of Intrathecally Administered Serotonin in the Rat by a Selective 5-HT3Receptor Antagonist”, Neuroscience Letters, vol. 95, pp. 313-317 (1988).
Giordano et al., “Differential Analgesic Actions of Serotonin 5-HT3Receptor Antagonists in the Mouse”, Neuropharmacology, vol. 28, No. 4, pp. 423-428 (1989).
Grubb et al., “A Study of 5-HT-Receptors Associated With Afferent Nerves Located in Normal and Inflamed Rat Ankle Joints”, Agents and Actions, vol. 25, Nos. 3 and 4, pp. 216-218 (1988).
Stratz et al., “Topical Treatment of Inflammatory Joint Affections With the 5-HT3 Receptor Antagonist Tropisetron”, Letter to the Editor (1999).
Chemical Abstracts XP-002149133 Fujii et al., “Prophylactic Antiemetic Therapy With Granisetron-Dexamethasone Combination in Women Undergoingg Breast Surgery”, Acta. Anaesthesiologica Scandinavica, vol. 42, No. 9, pp. 1038-1042 (1998)—[PREV199800515648].
Chemical Abstracts XP-002149135 Pramanik et al., “Serotonin-3 (5HT3) Receptor Antagonists Modulate Antinociceptive Responses in Mice”, Indian Journal of Physiology and Allied Sciences, vol. 50, No. 4, pp. 168-172 (1996)—[PREV199799649054].
Chemical Abstracts XP-002149136 Samborski et al., “The 5-HT3Blockers in the Treatment of the Primary Fibromyalgia Syndrome: A 10-Day Open Study With Tropisetron At a Low Dose”, Materia Medica Polona, vol. 28, No. 1, pp. 17-19 (1996)—[PREV199799477436].
Chemical Abstracts XP-002149137 Fujii et al., “Granisetron and Dexamethasone Provide More Improved Prevention of Postoperative Emesis Than Granisetron Alone in Children”, Canadian Journal of Anaesthesia, vol. 43, No. 12, pp. 1229-1232 (1996)—[PREV199799339428].
Chemical Abstracts XP-002149138 Moser, “The Effect of 5-HT3Receptor Antagonists on the Writhing Response in Mice”, General Pharmacology, vol. 26, No. 6, pp. 1301-1306 (1995)—[PREV199598457877].
Chemical Abstracts XP-002149142 Eschalier et al., “Influence of a Specific 5-HT3 Antagonist on Carrgeenan-Induced Hyperalgesia in Rats”, vol. 36, No. 2 (1989)—[PREV198987128603].
Doak et al., “Formalin-Induced Nociceptive Behavior and Edema: Involvement of Multiple Peripheral 5-Hydroxytryptamine Receptor Subtypes”, Neuroscience, vol. 80, No. 3, pp. 939-949 (1997).
Cunningham et al., “Optimum Anti-Emetic Therapy For Cisplatin Induced Emesis Over Repeat Courses: Ondansetron Plus Dexamethasone Compared With Metoclopramide, Dexamethasone Plus Lorazepam”, Annals of Oncology, vol. 7, No. 3, pp. 277-282 (1996).
Chemical Abstracts XP-002149157 Botella et al., “Intracolonic Glycerol Induces Abdominal Contractions in Rats: Role of 5-HT3 Receptors”, Fundamental & Clinical Pharmacology, vol. 12, No. 6, pp. 619-623 (1998)—[PREV 199900012906].
Chemical Abstracts XP-002149158 Samborski et al., “New Concept of Pharmacological Treatment of Fibromyalgia. Do Exist Two Subgroups of Fibromyalgia Patients?”, Reumatologia, vol. 36, No. 2, pp. 144-150 (1998)—[PREV199800453416].
Rosenstein, Abstract XP-000886228, Antinociceptive Effects of Microdialysis Administration of 5-HT1A and 5 HTReceptor Aagonists and Antagonists in a Model of Acute Arthritis. Society for Neurosciende Abstracts, US, Society for Neuroscience, vol. 23, No. p. 1540.
Faerber Lothar
Mueller Wolfgang
Stratz Thomas
Kwon Brian-Yong S
Novasearch AG
Wenderoth , Lind & Ponack, L.L.P.
LandOfFree
Use of 5-HT 3 receptor antagonists for treating... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of 5-HT 3 receptor antagonists for treating..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of 5-HT 3 receptor antagonists for treating... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2779600